Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,520 across all filing types
Latest filing 2023-12-20 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
FIRST LETTER AND REPLY FORM - ELECTIONS AS TO MEANS OF RECEIPT OF CORPORATE COMMUNICATIONS
Regulatory Filings Classification · 95% confidence The document is a letter to shareholders regarding their election of the means of receipt of future corporate communications from the company. It explains options for receiving documents such as annual reports, interim reports, notices of meetings, circulars, and proxy forms either electronically or in printed form. It includes a reply form for shareholders to indicate their preference. There is no actual financial data, report content, or detailed financial analysis present. The document is an announcement or notification about how shareholders can receive future reports and communications, not the reports themselves. It fits the description of a Regulatory Filing (RNS) as a general regulatory announcement and communication with shareholders about corporate communication preferences.
2023-12-20 English
VOLUNTARY ANNOUNCEMENT - SUBMISSION OF NEW DRUG APPLICATION FOR IRINOTECAN LIPOSOME INJECTION TO U.S. FDA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the submission of a New Drug Application (NDA) for a pharmaceutical product to the U.S. FDA. It is an announcement of a regulatory milestone related to drug approval, not a financial report, earnings release, or management discussion. The document is relatively short (3331 characters) and serves as a public disclosure of a significant corporate event. It does not contain financial statements, audit information, or detailed management analysis. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2023-12-18 English
VOLUNTARY ANNOUNCEMENT - DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULPHATE ORALLY DISINTEGRATING TABLETS OBTAINS CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the clinical trial approval of a new drug product. It is an announcement of a regulatory milestone rather than a financial report, management change, or shareholder meeting material. The document is relatively short (2384 characters) and does not contain financial data, management discussion, or detailed report content. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a general regulatory announcement category, as it informs the market about a significant company development related to product approval. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-12-12 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2023
Regulatory Filings Classification · 95% confidence The document is a monthly return report detailing movements in issued shares, share options, and other related securities information for CSPC Pharmaceutical Group Limited. It is addressed to the Hong Kong Exchanges and Clearing Limited and follows the format of a regulatory submission under the Exchange Listing Rules. The content focuses on share capital movements and confirmations, without containing financial statements, earnings data, or management commentary. It is a regulatory compliance filing reporting share capital and share option movements rather than a financial report or announcement of voting results. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory compliance documents that do not fit other specific categories.
2023-12-04 English
VOLUNTARY ANNOUNCEMENT - BIVALENT COVID-19 mRNA VACCINE (SYS6006.32) INCLUDED FOR EMERGENCY USE IN CHINA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the inclusion of their bivalent COVID-19 mRNA vaccine for emergency use in China. It contains no financial data, no regulatory form references, no voting results, no management changes, no earnings or financial statements, and no detailed report content. The document is relatively short (4013 characters) and serves as a public announcement of a significant product development and regulatory approval. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or others that require financial or governance data. It is not a report publication announcement since it does not mention any report being attached or published. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and public disclosures that do not fit other categories.
2023-12-01 English
QUARTERLY RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023
Interim / Quarterly Report Classification · 95% confidence The document is titled 'QUARTERLY RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023' and contains detailed unaudited consolidated financial results for the nine months period ending 30 September 2023. It includes revenue, profit, earnings per share, business segment performance, R&D expenses, regulatory updates, clinical trial progress, patents, and business development activities. The document is approximately 15,000 characters long, indicating it is a substantive report rather than a brief announcement. The content is consistent with a comprehensive interim or quarterly financial report providing actual financial data and analysis for a period shorter than a full fiscal year. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2023
2023-11-30 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.